November 29, 2012 at 03:00 AM EST
Lessons from the Liver Meeting: Sagient’s John Tucker Names Companies that Could Reignite the Hepatitis C Industry
The Life Sciences Report: You have just returned from the 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston (“The Liver Meeting”). I know it took place . . . → Read More: Lessons from the Liver Meeting: Sagient’s John Tucker Names Companies that Could Reignite the Hepatitis C Industry

The Life Sciences Report: You have just returned from the 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston (“The Liver Meeting”). I know it took place over five days, but could you briefly talk about the focus?

John Tucker: The AASLD meeting covers a broad range of issues around diseases of the liver—everything from alcoholic liver disease to priority rules for liver transplants to viral hepatitis. It is wide-ranging, but recent developments in the treatment of hepatitis C (HCV) were a major focus, simply because there has been so … [visit site to read more]

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here